Introduction
============

Diabetic retinopathy (DR) is one of the most common complications of diabetes and the leading cause of irreversible visual loss in people of working age in the United States \[[@r1]\]. The etiology of DR is complex and largely unknown. Hyperglycemia and long duration of diabetes along with hypertension are widely recognized as major risk factors for its development \[[@r2],[@r3]\]; however, these factors seem to explain only a part of the risk of DR \[[@r4],[@r5]\]. In clinical practice, for example, some patients with poorly controlled diabetes or a long duration of diabetes do not develop retinopathy, whereas others with relatively good glycemic control have advanced retinopathy \[[@r6]\]. Accumulated evidence has suggested that genetic factors may play a role in the development and progression of DR, with heritability estimated to be as high as 27% \[[@r7]\] for DR and 50% for proliferative diabetic retinopathy (PDR) \[[@r8]\].

Several studies have used a genome-wide association approach \[[@r9]-[@r12]\] and multipoint sib-pair analysis \[[@r13],[@r14]\] to detect regions of the genome that potentially contain genes involved in the etiology of DR. While different regions of the genome have been implicated, the reported regions were not consistently identified among the studies. In addition, many studies have taken a candidate gene approach to investigate the genetic etiology of DR, implicating the potential candidate genes in DR etiology, which include genes for PPARγ \[[@r15]\], vascular endothelial growth factor (VEGF) \[[@r16]-[@r19]\], erythropoietin (EPO) \[[@r20],[@r21]\], aldose reductase (AKR1B1) \[[@r22]-[@r25]\], protein kinase C (PKC)-β \[[@r26],[@r27]\], angiotensin-converting enzyme (ACE) \[[@r28]\], and intercellular adhesion molecule 1 (ICAM-1) \[[@r29]-[@r31]\]. The validity of these results, however, remains unconfirmed, with few of the reported susceptibility variants having been consistently replicated \[[@r25]\].

Kinase insert domain receptor (KDR), also called VEGF receptor (VEGFR) 2, is believed to be responsible for the majority of the angiogenic and permeability-enhancing effects of VEGF \[[@r32],[@r33]\]. An increase expression of KDR has been reported in the retinas from diabetic rats \[[@r34],[@r35]\]. One study investigated the fibrovascular tissues obtained from 22 PDR patients and suggested the co-expression of KDR and neuropilin-1 facilitated fibrovascular proliferation in DR \[[@r36]\]. Moreover, microvascular expression of KDR was found to be associated with leaky vessels in diabetic retina from eyes of diabetic donors as compared to the retina from eyes of nondiabetic control donors \[[@r37]\]. Taken together, these findings imply that KDR might be a major contributor in the pathogenesis of DR. Furthermore, the KDR gene has been found to be associated with other pathogenic conditions featured for vascular permeability and angiogenesis, such as age-related macular degeneration (AMD) \[[@r38]\], cancer \[[@r39]\], and coronary heart/artery disease \[[@r40],[@r41]\]. However, genetic association studies with DR have not been performed for the KDR gene. In this study, we tested whether the candidate genes, including PPARγ, VEGF, EPO, AKR1B1, PKC-β, ACE, and ICAM-1 genes as well as the KDR gene, were associated with DR in our independent cohort of Chinese patients with T2DM.

Methods
=======

Subjects and clinical evaluation
--------------------------------

The study protocol was approved by the Ethics Committee of Beijing Tongren Hospital (TRECKY200907) and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants before their enrollment. Patients with T2DM were recruited between November 2009 and September 2011 from the Desheng Community of urban Beijing. Diabetes was defined as a self-reported history of physician-diagnosed T2DM treated with insulin, oral hypoglycemic agents, or diet only; or by a fasting plasma glucose (FPG) concentration of 7.0 mmol/l (126 mg/dl) or more in at least two previous examinations; or a random plasma glucose concentration of ≥11.1 mmol/l (200 mg/dl). All subjects underwent a standardized evaluation consisting of a questionnaire, ocular and anthropometric examinations, and a laboratory test. The questionnaire elicited basic information (age, sex, ethnicity, income, education), lifestyle information (such as smoking and alcohol intake), health status information (such as the use of insulin therapy and any history of systemic diseases), and family history of diseases. Anthropometric parameters included body weight and height, waist and hip circumference, and three measurements, 5 min apart, of blood pressure in a resting state. Body mass index (BMI, kg/m^2^) was calculated according to the height and weight of the participant, and waist-to-hip ratio was calculated. A comprehensive ophthalmological examination included corrected visual acuity, slit-lamp biomicroscopy, and dilated fundus photography. Seven fields of 30°color fundus photographs with stereoscopic images of the optic disc and macula were taken through the dilated pupils of each patient, using a digital fundus camera (Zeiss Visucam Pro; Oberkochen, Germany).

Based on the duration of diabetes and grading of fundus photographs, patients were assigned to the diabetic-without retinopathy (DWR) group if they had more than 10 years of T2DM with no signs of DR (microaneurysms, hemorrhages, exudates) or if they had more than 15 years of T2DM with fewer than five microaneurysms. Patients with five or more microaneurysms in at least one eye were assigned to the DR group. Patients who did not meet the DWR or DR criteria were excluded from this study. The duration of diabetes was defined as the interval between the first diagnosis of diabetes and the time of enrollment in the present study.

Laboratory assays
-----------------

Fasting venous blood samples were collected for measurement of FPG, glycosylated hemoglobin A1c (HbA1c), creatinine, uric acid, and lipid profile (levels of total cholesterol, triglycerides, and high-density and low-density lipoprotein cholesterol), which were measured in an automated system with reagents for routine biomarkers. HbA1c was assessed by the enzymatic method using a Hitachi analyzer 7080 (Hitachi, Ibaraki, Japan). A first-void, midstream, morning, spot urine sample was collected, and albuminuria was measured by immunonephelometry with a Roche/Cobas C501 analyzer (Ibaraki). High albuminuria was defined as ≥20 mg/l.

Candidate genes and single-nucleotide polymorphisms selection
-------------------------------------------------------------

Eight candidate genes that are involved in the pathogenesis of DR or previously identified as being associated with DR were tested, including the PPARγ, VEGF and its receptor (KDR), EPO, AKR1B1, PKC-β, ACE and ICAM-1 genes. Twenty-six single-nucleotide polymorphisms (SNPs) in these genes were chosen initially for availability of assays, informativeness, and spacing across the gene. More information about the candidate genes is given in [Table 1](#t1){ref-type="table"}. It should be noted that the VEGF gene has been reported in previous literature \[[@r16]\], and the present study repeated the association between the VEGF gene and DR in an expanded larger sample size.

###### Description of candidate genes investigated

  **Gene**     **Gene function**                                                                                                                                                            **Locus**    **References**
  ------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ --------------------------------------------------------------------------------------------------
  **PPARγ**    responsible for differentiation of fibroblasts to adipocytes and regulation of their function                                                                                3p25         Maciej et al. 2008 \[[@r13]\]
  **KDR**      functions as the main mediator of VEGF-induced endothelial permeability, proliferation, survival, migration, tubular morphogenesis and sprouting                             4q11-q12     Galan et al. 2010 \[[@r46]\]
  **VEGF**     a critical angiogenic and vasopermeability factor that is upregulated in various conditions involving retinal ischemia                                                       6p12         Churchill et al. 2008 \[[@r15]\] Al-Kateb et al. 2007 \[[@r16]\]
  **EPO**      been linked to angiogenesis, vasculogenesis, and neuroprotection                                                                                                             7q21--7q22   Tong et al. 2008 \[[@r18]\] Abhary et al. 2010 \[[@r19]\]
  **AKR1B1**   the first and rate-limiting enzyme in the polyol pathway                                                                                                                     7q35         Richeti, F et al. 2007 \[[@r22]\] Abhary et al. 2009 \[[@r23]\]
  **PKC-β**    PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways                                       16p11.2      Uthra et al. 2010 \[[@r24]\] Ikeda et al. 2004 \[[@r25]\]
  **ACE**      involved in the conversion of angiotensin I to angiotensin II (ATII).                                                                                                        17q23        Kondo et al. 2009 \[[@r26]\]
  **ICAM-1**   a member of the immunoglobulin superfamily of adhesion molecules, involved in blood-retina barrier breakdown, capillary nonperfusion and endothelial cell damage and death   19p13        Kamiuchi, et al. 2002 \[[@r21]\] L. Liu, et al. 2006 \[[@r22]\] Petrovic, et al. 2008 \[[@r23]\]

Locus: the chromosomal region of gene; p: long arm of chromosome; q: short arm of chromosome

Genotyping
----------

Blood samples were collected from all participants and stored at −80 °C before DNA extraction. Genomic DNA was extracted from venous blood leukocytes using a genomic DNA extraction and purification kit (TIANamp Swab DNA Kit; Tiangen Biotech, Beijing, China). Study participants were genotyped for the SNPs using Sequenom MassARRAY technology (Bioyong Technologies, Beijing, China). All DNA samples passing initial quality checks were plated at a concentration of ≥5 ng/μl for processing on the platform. Quality measures taken into account for genotyped SNPs to be excluded from the subsequent analysis were minor allele frequency (MAF) \<0.05, genotyping success \<80%, and failed Hardy--Weinberg equilibrium (HWE) test in control samples (p\<0.001). Quality control criteria for each SNP were implemented in our data set.

Statistical analysis
--------------------

Statistical analysis was performed using the R statistical analysis package. Baseline characteristics of diabetic patients in the DR and DWR groups were compared using a *t* test for continuous variables or a chi-square test for categorical variables. The genotype frequencies of genes were checked for HWE in all groups using a chi-square test. The chi-square test was also used to analyze the distribution of genotypes and alleles. When the expected frequency was less than 5, Fisher's exact test was used. The pairwise linkage disequilibrium was calculated using [Haploview](http://www.broad.mit.edu/mpg/haploview), version 4.2 (Broad Institute, Cambridge, MA). Univariate and multivariate logistic regression analyses were performed to identify the association between SNPs/haplotypes and the presence of DR. Statistical results were expressed as p values, odds ratios (OR), and 95% confidence intervals (CI). The Bonferroni correction (p\<0.05 divided by the number of SNPs analyzed) was used to account for multiple testing.

Results
=======

In total, 1,433 subjects with T2DM were enrolled from the community, of which, 500 subjects (284 in the DWR group and 216 in the DR group) participated in the genetic study based on the inclusion criteria. The distribution of demographic, behavioral, and clinical characteristics of participants are listed in [Table 2](#t2){ref-type="table"}. In the DR group, 59 patients were further classified as PDR. Compared with the DWR group, individuals in the DR group had a younger age of diabetic onset (p=0.008); higher percentage of high albuminuria (p\<0.001); higher levels of creatinine (p=0.027), FPG (p\<0.001), and HbA1c (p\<0.001); and were more likely to use insulin (p\<0.001). Duration of diabetes in the DWR group was longer than the DR group (p=0.013), which could be due to the definition of DWR in this study (more than 10 years of T2DM without retinopathy). No statistically significant differences were found between the DR and DWR groups in terms of gender, BMI, waist-to-hip ratio, blood pressure, serum levels of uric acid, or lipid profile.

###### Clinical and biochemical markers for the studied groups

  **Clinical characteristics**      **DWR (n=284)**   **DR (n=216)**   **p value**
  --------------------------------- ----------------- ---------------- -------------
  Age of diabetic onset (years)     52.7±7.61         50.67±9.41       0.008
  Sex (Male/Female)                 111/173           103/113          0.054
  Duration of diabetes (years)      14.79±4.97        13.44±7.22       0.013
  BMI (kg/m^2^)                     25.26±3.95        25.8±4.13        0.14
  WHR                               0.92±0.06         0.93±0.06        0.5
  High albuminuria(-/+)             240/38            143/68           \<0.001
  Systolic blood pressure (mmHg)    136.7±16.65       138.5±17.18      0.22
  Diastolic blood pressure (mmHg)   77.65±9.36        79.23±9.69       0.066
  Insulin therapy (yes/no)          92/191            118/97           \<0.001
  HbA1c (%)                         6.97±1.40         7.84±1.70        \<0.001
  FPG (mmol/l)                      8.09±2.43         9.22±3.21        \<0.001
  Creatinine (µmol/l)               67.43±17.69       73.66±49.84      0.027
  Uric acid (µmol/l)                281.9±82.42       281.1±76.58      0.98
  Cholesterol (mmol/l)              5.05±0.98         5.18±1.17        0.19
  Triglycerides (mmol/l)            1.55±0.93         1.73±1.52        0.11
  HDL cholesterol (mmol/l)          1.25±0.30         1.23±0.30        0.38
  LDL cholesterol (mmol/l)          3.07±0.83         3.08±0.90        0.83

The data are expressed as mean ± standard deviation (SD) or number of subjects. Differences between diabetic retinopathy (DR) and diabetic without retinopathy (DWR) groups were compared using *t* test or Chi-square test. BMI, body mass index; WHR, waist and hip ratio; HbA1c, glycosylated hemoglobin A1c; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Basic information of SNPs analyzed with allelic distributions is shown in [Table 3](#t3){ref-type="table"}. Out of the 26 SNPs selected, [rs11645239](http://www.ncbi.nlm.nih.gov/snp/?term=rs11645239) in the PKC-β gene had a low genotyping call rate (\<52%); [rs1805192](http://www.ncbi.nlm.nih.gov/snp/?term=rs1805192) in the PPARγ gene and [rs1799969](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799969) in the ICAM-1 gene had a minor allele frequency of less than 5% in the studied population. These three SNPS were not studied further. The remaining 23 SNPs were tested in the DR and DWR groups for any departure from HWE. All were in HWE except [rs3900008](http://www.ncbi.nlm.nih.gov/snp/?term=rs3900008) (p\<0.001), which failed to be genotyped in 53 individuals, indicating a possible genotyping error. The SNP [rs3900008](http://www.ncbi.nlm.nih.gov/snp/?term=rs3900008) was therefore excluded, and a total of 22 SNPs were included for subsequent analysis. For each of the SNPs evaluated, the number of participants varied slightly depending on the genotype call rate (≥94%).

###### Basic information of Alleles and allele association results Between DR and DWR groups

  **Gene**     **locus**     **SNP**     **position**   **Minor**   **MAF**   **HWpval**        **OR (CI)**   **P**             
  ------------ ------------- ----------- -------------- ----------- --------- ----------------- ------------- ----------------- -----------
  **PPARγ**    **3**         rs1805192   12,396,238     G           0                                                           
  **KDR**      **4**         rs2071559   55,687,123     C           0.34      0.39              0.022         1.41(1.07,1.86)   **0.011**
  rs13109660   55,665,437    A           0.31           0.63        0.49      1.06(0.8,1.41)    0.66                            
  rs1870378    55,661,210    A           0.48           0.67        0.33      0.92(0.71,1.21)   0.55                            
  rs1870377    55,667,731    A           0.48           0.4         0.73      0.95(0.73,1.23)   0.67                            
  **VEGF**     **6**         rs699947    43,844,367     A           0.28      0.009             0.51          1.63(1.22,2.18)   **0.001**
  rs833061     43,845,464    C           0.28           0.021       0.33      1.53(1.14,2.04)   **0.003**                       
  rs13207351   43,845,772    A           0.28           0.01        0.41      1.58(1.18,2.12)   **0.001**                       
  rs2010963    43,846,328    C           0.44           0.41        0.9       0.87(0.67,1.13)   0.29                            
  rs833069     43,850,557    G           0.44           1           0.9       0.92(0.71,1.2)    0.53                            
  rs2146323    43,853,073    A           0.26           0.003       0.49      1.52(1.13,2.05)   **0.004**                       
  rs3025021    43,857,141    T           0.16           0.58        1         1.36(0.95,1.97)   0.083                           
  rs3025039    43,860,514    T           0.09           1           0.38      1.34(0.96,1.88)   0.077                           
  **EPO**      **7**         rs507392    100,157,872    C           0.2       0.4               0.03          0.93(0.67,1.28)   0.64
  rs551238     100,159,464   C           0.2            0.39        0.045     1.04(0.75,1.45)   0.8                             
  rs1617640    100,155,234   G           0.19           0.1         0.14      1.18(0.85,1.66)   0.31                            
  **AKR1B1**   **7**         rs759853    133,794,498    A           0.07      0.79              0.34          1.31(0.92,1.87)   0.11
  **PKC-β**    **16**        rs3900007   23,754,453     G           0.42      0.49              0.22          1.01(0.78,1.31)   0.95
  rs3900008    23,754,514    C           0.3            \<0.001     \<0.001   1.05(0.78,1.41)   0.75                            
  rs11645239   23,754,563    G           0.36                                                                                   
  rs2575390    23,754,255    G           0.06           1           1         0.95(0.53,1.69)   0.85                            
  rs3760106    23,753,297    A           0.06           1           1         1.02(0.57,1.84)   0.95                            
  **ACE**      **17**        rs1800764   58,904,261     C           0.39      1                 1             1.23(0.94,1.6)    0.12
  rs9896208    58,929,841    T           0.42           0.26        0.021     0.95(0.73,1,24)   0.71                            
  **ICAM-1**   **19**        rs5498      10,256,683     G           0.31      0.64              0.1           1.32(1,1.75)      **0.044**
  rs1799969    10,255,792    A           0.003                                                                                  

MAF: minor allele frequency; HWpval: p value for Hardy--Weinberg (H-W) equilibrium; OR: odds ratio; CI:95% confidence interval; Genotype distributions for SNPs were in Hardy--Weinberg (H-W) equilibrium, except [rs3900008](http://www.ncbi.nlm.nih.gov/snp/?term=rs3900008) in both groups.

[Table 4](#t4){ref-type="table"} shows the genotypic distribution in the DR and DWR groups for the 22 informative SNPs. A strong association with DR was detected at three promoter variants ([rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947)) and one intronic SNP ([rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323)) in the VEGF gene, with the minor alleles of SNPs [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), and [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323) showing a similar magnitude of risk (OR≥1.52; p\<0.003). The ORs for the homozygote minor alleles were 3.80 (95% CI: 1.91-7.57) for [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), 3.6 (95% CI: 1.79- 7.22) for [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), 3.7 (95% CI: 1.86-7.39) for [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), and 2.8 (95% CI: 1.46-5.37) for the intronic SNP [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323). The three promoter variants [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) in the VEGF gene showed strong linkage disequilibrium (r^2^≥0.98). SNP [rs2071559](http://www.ncbi.nlm.nih.gov/snp/?term=rs2071559) in the KDR gene was also significantly associated with DR with an OR of 1.41 (95% CI: 1.07-1.86) for the minor allele and 1.57 (95% CI: 1.05-2.28) for the minor homozygote.

###### Genotype frequencies of polymorphisms in the studied groups

  **Gene**     **SNP**     **Sample size**   **genotype**   **DR**      **DWR**            **OR (CI)**   **p-value**
  ------------ ----------- ----------------- -------------- ----------- ------------------ ------------- -------------
  KDR          rs2071559   492               TT             84(39.3)    141(50.7)                        0.034
                           CT                95(44.4)       103(37.1)   1.73 (1,2.98)                    
                           CC                35(16.4)       34(12.2)    1.57 (1.05,2.28)                 
  rs1870377    490         TT                53(24.8)       78(28.3)                       0.6           
                           TA                113(52.8)      134(48.6)   1.24 (0.81,1.91)                 
                           AA                48(22.4)       64(23.2)    1.1 (0.66,1.84)                  
  rs1870378    471         GG                54(26.9)       80(29.6)                       0.8           
                           GA                97(48.3)       126(46.7)   1.14 (0.74,1.76)                 
                           AA                50(24.9)       64(23.7)    1.16 (0.7,1.92)                  
  rs13109660   490         GG                102(47.9)      127(45.8)                      0.9           
                           GA                93(43.7)       125(45.1)   0.93 (0.64,1.35)                 
                           AA                18(8.5)        25(9)       0.9 (0.46,1.73)                  
  VEGF         rs699947    495               CC             105(48.6)   162(58.1)                        \<0.001
                           CA                79(36.6)       104(37.3)   1.17 (0.8,1.72)                  
                           AA                32(18.4)       13(4.7)     3.80 (1.91,7.57)                 
  rs833061     491         TT                104(49.1)      158(56.6)                      0.001         
                           CT                78(36.8)       108(38.7)   1.1 (0.75,1.61)                  
                           CC                30(14.2)       13(4.7)     3.6 (1.79,7.22)                  
  rs13207351   491         GG                105(48.8)      158(57.2)                      \<0.001       
                           GA                78(36.3)       105(38)     1.12 (0.76,1.64)                 
                           AA                32(14.9)       13(4.7)     3.7 (1.86,7.39)                  
  rs2146323    490         CC                112(52.3)      167(60.5)                      0.006         
                           CA                72(33.6)       93(33.7)    1.15 (0.78,1.7)                  
                           AA                30(14)         16(5.8)     2.8 (1.46,5.37)                  
  rs3025021    491         TT                5(2.4)         9(3.2)                         0.21          
                           CT                48(22.6)       81(29)      1.07 (0.34,3.37)                 
                           CC                159(75)        189(67.7)   1.51 (0.5,4.61)                  
  rs833069     497         GG                40(18.6)       58(20.6)                       0.82          
                           GA                105(48.8)      138(51.8)   1.1 (0.69,1.78)                  
                           AA                70(18.6)       86(30.5)    1.18 (0.71,1.97)                 
  rs2010963    495         GG                70(32.6)       84(30)                         0.47          
                           GC                111(51.6)      140(50)     0.95 (0.64,1.42)                 
                           CC                34(15.8)       56(20)      0.73 (0.43,1.24)                 
  rs3025039    498         CC                137(63.7)      198(70.0)                      0.15          
                           CT                69(32.1)       47(28.3)    2.6 (0.85,7.93)                  
                           TT                9(4.2)         5(1.8)      1.25 (0.85,1.84)                 
  ICAM-1       rs5498      492               AA             92(42.8)    138(49.8)                        0.078
                           GA                100(46.5)      123(44.4)   1.22 (0.84,1.77)                 
                           GG                23(10.7)       16(5.8)     2.16 (1.08,4.30)                 
  EPO          rs507392    496               TT             141(65.3)   181(64.6)                        0.68
                           CT                65(30.1)       81(28.9)    1.03 (0.69,1.53)                 
                           CC                10(4.6)        18(6.4)     0.71 (0.32,1.59)                 
  rs551238     494         AA                141(65.3)      182(65.5)                                    
                           CA                65(30.1)       79(28.4)    1.06 (0.72,1.58)   0.74          
                           CC                10(4.6)        17(6.1)     0.76 (0.34,1.71)                 
  rs1617640    491         TT                146(69.2)      182(65)                                      
                           GT                55(26.1)       82(29.3)    0.84 (0.56,1.25)   0.61          
                           GG                10(4.7)        16(5.7)     0.78 (0.34,1.77)                 
  AKR1B1       759853      471               GG             145(70.7)   167(62.8)                        
                           GA                54(26.3)       91(34.2)    0.68 (0.46,1.02)   0.18          
                           AA                6(2.9)         8(3.0)      0.86 (0.29,2.55)                 
  ACE          1800764     494               TT             88(40.9)    98(35.1)                         0.31
                           CT                99(46.0)       134(48)     0.83 (0.56,1.23)                 
                           CC                28(13)         47(16.8)    0.65 (0.38,1.14)                 
  rs9896208    496         CC                79(36.6)       84(30)                         0.056         
                           TC                97(44.9)       156(55.7)   0.66 (0.44,0.98)                 
                           TT                40(18.5)       40(14.3)    1.06 (0.62,1.82)                 
  PKC-β        3,900,007   496               AA             69(31.9)    99(35.4)                         0.36
                           GA                111(51.4)      126(45)     1.26 (0.85,1.88)                 
                           GG                36(16.7)       55(19.6)    0.94 (0.56,1.58)                 
  2575390      499         CC                193(89.4)      251(88.7)                      0.95          
                           CG                22(10.2)       31(11.0)    0.92 (0.52,1.64)                 
                           GG                1(0.5)         1(0.4)      1.3 (0.08,20.92)                 
  3760106      492         GG                190(89.2)      248(88.9)                      0.97          
                           GA                22(10.3)       30(10.8)    1.31 (0.08,21)                   
                           AA                1(0.5)         1(0.4)      0.96 (0.54,1.71)                 

Data are expressed as number (%).The p value represents comparison between DR and diabetic without retinopathy (DWR) groups, using χ2 or Fisher's exact test.

[Table 5](#t5){ref-type="table"} presents the multivariate analyses data adjusted for variables including the age of diabetic onset, duration of diabetes, high albuminuria, insulin use, HbA1c, and creatinine levels. The association with DR remained statistically significant with the homozygous genotype of the minor allele for SNPs [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) (OR=3.74, 95% CI: 1.75-8.00), [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061) (OR=3.50, 95% CI: 1.62-7.54), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351) (OR=3.64, 95% CI: 1.71-7.77), and [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323) (OR=2.88, 95% CI: 1.4-5.93) in the VEGF gene as well as SNP [rs2071559](http://www.ncbi.nlm.nih.gov/snp/?term=rs2071559) (OR=1.88, 95% CI: 1.01-3.48) in the KDR gene. However, only [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) and [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351) in the VEGF gene remained statistically significant after Bonferroni correction for the 22 SNPs analyzed. No statistically significant association with DR was found for all other SNPs in genes for EPO, AKR1B1, PKC-β, ACE, and ICAM-1.

###### Association analysis of polymorphisms in multivariate models

  **Gene**     **SNP**     **genotype**       **Ajusted OR (CI)**   **P value**
  ------------ ----------- ------------------ --------------------- -------------
  KDR          rs2071559   TT                                       0.05
               CT          1.57 (1.01,2.44)                         
               CC          1.87 (1.01,3.48)                         
  rs1870377    TT                             0.64                  
               TA          1.13 (0.69,1.85)                         
               AA          0.88 (0.48,1.6)                          
  rs1870378    GG                             0.79                  
               GA          1.1 (0.66,1.81)                          
               AA          0.91 (0.5,1.66)                          
  rs13109660   GG                             0.93                  
               GA          1.01 (0.48,2.13)                         
               AA          1.09 (0.7,1.68)                          
  VEGF         rs699947    CC                                       0.002
               CA          1.26 (0.82,1.95)                         
               AA          3.74 (1.75,8.00)                         
  rs833061     TT                             0.004                 
               CT          1.19 (0.77,1.85)                         
               CC          3.50 (1.62,7.54)                         
  rs13207351   GG                             0.002                 
               GA          1.22 (0.79,1.89)                         
               AA          3.64 (1.71,7.77)                         
  rs2146323    CC                             0.014                 
               CA          1.14 (0.73,1.77)                         
               AA          2.88 (1.4,5.93)                          
  rs3025021    TT                                                   
               CT          0.75 (0.2,2.78)    0.22                  
               CC          1.14 (0.32,4.06                          
  rs833069     GG                                                   
               GA          1.09 (0.63,1.89)   0.63                  
               AA          1.3 (0.73,2.34)                          
  rs2010963    GG                                                   
               GC          0.89 (0.56,1.41)   0.51                  
               CC          0.7 (0.38,1.28)                          
  rs3025039    CC                             0.23                  
               CT          1.23 (0.79,1.92)                         
               TT          2.8 (0.76,10.27)                         
  ICAM-1       rs5498      AA                                       0.091
               GA          1.44 (0.94,2.22)                         
               GG          2.04 (0.94,4.44)                         
  EPO          rs507392    TT                                       0.88
               CT          1.02 (0.65,1.61)                         
               CC          0.8 (0.32,2.02)                          
  rs551238     AA                             0.94                  
               CA          1.07 (0.67,1.68)                         
               CC          0.92 (0.36,2.36)                         
  rs1617640    TT                                                   
               GT          0.85 (0.53,1.36)   0.79                  
               GG          0.94 (0.36,2.41)                         
  AKR1B1       759853      GG                                       0.11
               GA          0.62 (0.39,0.99)                         
               AA          0.59 (0.17,2.05)                         
  ACE          1800764     TT                                       0.33
               CT          0.87 (0.56,1.37)                         
               CC          0.62 (0.33,1.16)                         
  rs9896208    CC                                                   
               TC          0.62 (0.39,0.97)   0.097                 
               TT          0.88 (0.47,1.63)                         
  PRK-β        3900007     AA                                       0.82
               GA          1.14 (0.72,1.8)                          
               GG          1.17 (0.64,2.14)                         
  2575390      CC                             0.78                  
               CG          0.89 (0.46,1.71)                         
               GG          2.73 (0.1,73.85)                         
  3760106      GG                             0.81                  
               GA          2.67 (0.1,71.35)                         
               AA          0.92 (0.48,1.77)                         

Multiple logistic regression analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) by comparing diabetic retinopathy (DR) group with diabetic without retinopathy (DWR) group, which include the most significant SNP at kinase insert domain receptor gene (KDR) gene ([rs2071559](http://www.ncbi.nlm.nih.gov/snp/?term=rs2071559)), vascular endothelial growth factor (VEGF) gene ([rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323)). Adjusted OR represents data after adjustment for covariates including age of diabetic onset, duration, high albuminuria, insulin use, glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose and creatinine levels.

Haplotype analysis revealed five SNP blocks ([Figure 1](#f1){ref-type="fig"}). Only two haplotypes in the VEGF gene showed strong evidence of an association with DR, and the others did not show any statistically significant association ([Table 6](#t6){ref-type="table"}). The frequency of haplotype ACGA in the VEGF gene, defined by the minor alleles of the three SNPs [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351) at the promoter region and [rs2010963](http://www.ncbi.nlm.nih.gov/snp/?term=rs2010963) at the 5′ untranslated region, was 32.4% in the DR group and 23.2% in the DWR group (p=0.002, OR=1.58, 95% CI: 1.19--2.10). The haplotype AA defined by the minor alleles of the SNPs [rs833069](http://www.ncbi.nlm.nih.gov/snp/?term=rs833069) and [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323) at intron 2 of the VEGF gene was 30.7% in the DR group and 22.5% in the DWR group (p=0.004), with an OR of 1.53 (95% CI: 1.15--2.04) for the increased risk of DR.

![Linkage disequilibrium plot generated by Haploview 4.2 software. Five haplotype blocks (bold) were identified for single-nucleotide polymorphisms (SNPs) in the kinase insert domain receptor, vascular endothelial growth factor gene, protein kinase C-β gene, and in erythropoietin gene. Linkage disequilibrium (LD) is displayed as the pairwise D' value multiplied by 100 and given for each SNP combination. Shading represents the magnitude and significance of the pairwise LD, with a red-to-white gradient reflecting higher-to-lower LD values. Red diamond without a number corresponds to a D' value of 1.0.](mv-v20-200-f1){#f1}

###### Haplotype association analysis between polymorphisms and risk of diabetic retinopathy in patients with type 2 diabetes mellitus

  **Haplotype blocks**   **DR group (%)**   **DWR group (%)**   **OR (95%CI)**      **Chi Square**   **p value**
  ---------------------- ------------------ ------------------- ------------------- ---------------- -------------
  Block 1                                                                                            
  AAG                    48.7               47.2                1.07 (0.82, 1.39)   0.26             61
  TGA                    29.5               31.2                0.93 (0.69, 1.23)   0.28             0.59
  TGG                    20.7               20.8                0.99(0.72--1.37)    0.001            0.98
  Block 2                                                                                            
  ACGA                   32.4               23.2                1.58 (1.19, 2.10)   9.87             0.002
  CTCG                   42.1               44.6                0.90 (0.69, 1.16)   0.68             0.41
  CTGG                   25.2               31.6                0.73(0.55, 0.97)    4.8              0.03
  Block 3                                                                                            
  AA                     30.7               22.5                1.53 (1.15, 2.04)   8.39             0.04
  AC                     25.8               32.4                0.72 (0.55, 0.96)   5.16             0.02
  GC                     43.4               44.8                0.94 (0.73, 1.21)   0.23             0.63
  Block 4                                                                                            
  CGA                    57.3               57.9                0.97(0.75, 1.26)    0.044            0.83
  CGG                    37.1               36.3                1.04(0.80, 1.35)    0.068            0.79
  GAG                    5.6                5.8                 0.97(0.57, 1.68)    0.009            0.92
  Block 5                                                                                            
  CCG                    17.5               20                  0.86(0.62, 1.20)    0.79             0.37
  TAT                    80.6               79.4                1.16(0.84, 1.61)    0.79             0.37

Data were given as frequency of each haplotype within diabetic retinopathy (DR) group or diabetic without retinopathy (DWR) group. Block 1 included [rs1870378](http://www.ncbi.nlm.nih.gov/snp/?term=rs1870378), [rs13109660](http://www.ncbi.nlm.nih.gov/snp/?term=rs13109660), and [rs1870377](http://www.ncbi.nlm.nih.gov/snp/?term=rs1870377) in kinase insert domain receptor gene. block 2 included promoter SNPs [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), [rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351) and [rs2010963](http://www.ncbi.nlm.nih.gov/snp/?term=rs2010963) at 5′ UTR, and Block3 included SNPs two intronic SNPs of [rs833069](http://www.ncbi.nlm.nih.gov/snp/?term=rs833069) [rs2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323) in vascular endothelial growth factor gene, Block4 included SNPs rs3760106 rs2575390 rs3900007 in protein kinase C-β gene, block 5, [rs1617640](http://www.ncbi.nlm.nih.gov/snp/?term=rs1617640) [rs507392](http://www.ncbi.nlm.nih.gov/snp/?term=rs507392) [rs551238](http://www.ncbi.nlm.nih.gov/snp/?term=rs551238) in erythropoietin gene. Only haplotypes with frequency over 3% were included in this table. OR indicates odds ratio and CI refers to confidence interval.

Discussion
==========

We analyzed the possible association between polymorphisms in eight candidate genes and DR in a well-defined cohort of Chinese patients with T2DM. Our data showed significant association between SNPs in the VEGF gene and the risk of DR after adjustment for possible confounding risk factors. However, no statistically significant association was found for other genes, including KDR, PPARγ, EPO, AKR1B1, PKC-β, ACE, and ICAM-1.

The pathogenesis of DR is complex with multifactorial biochemical causes influenced by genetic and environmental factors. Many vasoactive factors stimulated by hyperglycemia or oxidative stress have been identified \[[@r1]\]. Among them, VEGF has been characterized as a critical angiogenic and vasopermeability factor that is upregulated in various retinal ischemic disorders, such as retinopathy of prematurity, AMD, and DR \[[@r32]\], whereas anti-VEGF therapy has been shown to be effective for patients with AMD \[[@r42]\] or diabetic macular edema \[[@r43]\]. The human VEGF gene is highly polymorphic and has a large number of individual SNPs examined in relationship with DR \[[@r16]-[@r19],[@r44]\]. In our previous study, three SNPs ([rs833061](http://www.ncbi.nlm.nih.gov/snp/?term=rs833061), [rs13207351](http://www.ncbi.nlm.nih.gov/snp/?term=rs13207351), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947)) at the promoter region of the VEGF gene showed a strong association with the risk of DR \[[@r16]\]. This current study with an expanded sample size confirmed our previous report. Discussions of the three promoter SNPs have been described in detail in our previous literature \[[@r16]\]. Moreover, the association of DR with an intronic SNP r[s2146323](http://www.ncbi.nlm.nih.gov/snp/?term=rs2146323) in the VEGF gene has been suggested in this current study. Although the intronic region of VEGF is believed to contain binding sites for transcription factors that regulate VEGF production \[[@r45]\], there is no functional data to date on the intronic SNPs.

There are three high-affinity VEGF tyrosine kinase receptors: VEGFR-1, VEGFR-2 (KDR), and VEGFR-3 that are expressed mainly in the vascular endothelial cells \[[@r32],[@r33]\]. KDR is the primary responder to the VEGF signal regulating endothelial cell migration and proliferation \[[@r32],[@r33]\]. Several lines of evidence have implicated that KDR plays a role in the etiology of DR \[[@r34]-[@r37]\]. Although it became insignificant after Bonferroni correction, the present study suggested a possible association between the SNP [rs2071559](http://www.ncbi.nlm.nih.gov/snp/?term=rs2071559) in the KDR gene and DR. Further studies with a larger sample size to confirm this observation would be warranted. The present study failed to find an association of DR with other previously reported genes, including ACE, AKR1B1, PKC-β, PPARγ, ICAM-1, and EPO. Discrepancies between our study and previous reports could be due to different ethnic origin, diagnostic criteria, or sample size.

Strengths of the current study include the enrollment of participants from a relatively homogeneous population of a single community, collection of detailed information on a variety of risk factors, and the standardized fundus photograph and assessment of DR severity. Additionally, previous genetic association studies for DR have been limited to studies of one or a modest number of candidate genes \[[@r25],[@r46]\]. To our knowledge, this is the first and largest study in the Chinese population to address the question of whether multiple candidate genetic polymorphisms are associated with DR.

In summary, the present study confirmed our previous observation on the association between DR and VEGF polymorphisms independent of other clinical factors in the Chinese population. Moreover, a possible association between DR and KDR polymorphisms is suggested and further studies are warranted.

This work was supported by the National Basic Research Program of China (973 Program) Grant 2007CB512201, the Beijing Municipal Health Bureau Grant 2,009,208, and the Beijing Natural Science Foundation Grant 7,131,007.
